PROSCA 2023 Satellite Symposium: Professor Matthias Saar
Recorded from PROSCA 2023 in Malaga, Professor Matthias Saar (Director & Chairman of Urology and Uro-oncology – University Hospital RWTH Aachen, Germany) presents the Intermittent Androgen Deprivation Therapy (ADT) in the new era of hormonal therapy and highlights the alternative treatment options.
As part of the video below, Professor Saar discusses the following key topics:
- Landmark Prostate-Specific Anitgen (PSA) tests and overall survival outcomes in Metastatic hormone-sensitive prostate cancer (mHSPC)
- What is the future for ADT in intermittent therapy
- HERO trial results in mHSPC4
Watch video below
Duration : 05:17 min
Professor Matthias Saar
Professor Matthias Saar is director and chairman at the department of urology and urological oncology at the University Hospital Aachen, Germany. He obtained his degree in medicine at the Julius Maximilians University of Würzburg in Germany, and became a resident doctor at Saarland University in Homburg, Germany.
Dr. Saar was a postdoctoral scholar at Stanford University, USA, after which he became senior physician and consultant at the department of urology and paediatric urology of Saarland University in Homburg, Germany. He has expertise in uro-oncology with an emphasis on prostate cancer and minimally invasive surgery, especially robotic-assisted surgery.
Orgovyx® is the One & Only Oral ADT indicated for the treatment of:1-3
- Adult patients with advanced hormone -sensitive prostate cancer
- High-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy
- High-risk localised or locally advanced hormone dependent prostate cancer as a neo-adjuvant treatment prior to radiotherapy
References:
- ORGOVYX® Summary of Product Characteristics
- Fragkoulis C, et al. Arab Journal of Urology. 2021; 19(4):460-463
- National Institute for Health and Care Excellence. British National Formulary. Available from: https://bnf.nice.org.uk/drugs. Accessed: September 2024
- Shore N D, et al. New England Journal of Medicine. 2020; 382(23):2187-2196
Related Content
